67. 多発性嚢胞腎
[臨床試験数:186,薬物数:196(DrugBank:47),標的遺伝子数:35,標的パスウェイ数:146

Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02134899
(ClinicalTrials.gov)
October 14, 201428/4/2014The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsAn Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseDrug: Everolimus;Drug: Calcineurin inhibitors maintenanceAssistance Publique - Hôpitaux de ParisNovartisCompleted18 Years75 YearsAll3Phase 3France
2NCT01009957
(ClinicalTrials.gov)
June 20086/11/2009Everolimus on CKD Progression in ADPKD PatientsEverolimus on CKD (Chronic Kidney Disease) Progression in ADPKD PatientsPolycystic Kidney DiseasesDrug: EverolimusA. Manzoni HospitalNULLTerminated18 YearsN/ABoth71Phase 2/Phase 3Italy
3EUCTR2006-001485-16-FR
(EUCTR)
20/08/200723/07/2007A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDA multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD polycystic kidney disease
MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease
Product Name: Certican
Product Code: RAD001
INN or Proposed INN: Everolimus
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
300France;Austria;Germany
4EUCTR2006-001485-16-AT
(EUCTR)
15/12/200616/11/2006A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDA multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD polycystic kidney disease
MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease
Product Name: Certican Tabletten
Product Code: RAD001
INN or Proposed INN: Everolimus
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
300France;Austria;Germany
5NCT00414440
(ClinicalTrials.gov)
December 200620/12/2006Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseA Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Autosomal Dominant Polycystic Kidney DiseaseDrug: Placebo;Drug: EverolimusNovartis PharmaceuticalsNULLCompleted18 Years50 YearsAll431Phase 4Austria;France;Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-001485-16-DE
(EUCTR)
25/10/200619/01/2007A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDA multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD polycystic kidney disease
MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease
Product Name: Certican Tabletten
Product Code: RAD001
INN or Proposed INN: Everolimus
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
300France;Austria;Germany